Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025

Item

http://www.wikidata.org/entity/Q36851168

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025

@en

type

Item

label

Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025

@en

prefLabel

Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025

@en

P1476

Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025

@en

P2093

Gwendolyn B Scott

http://www.w3.org/2001/XMLSchema#string

Jennifer S Read

http://www.w3.org/2001/XMLSchema#string

Kunjal Patel

http://www.w3.org/2001/XMLSchema#string

Marcia Mitchell

http://www.w3.org/2001/XMLSchema#string

Yanling Huo

http://www.w3.org/2001/XMLSchema#string

P2860

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

Monitoring death and cancer in children born to HIV-infected women in England and Wales: use of HIV surveillance and national routine data.

Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer

Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception

Antiretroviral therapy during pregnancy and the risk of an adverse outcome.

Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study.

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.

U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis.

P304

92-102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JPIDS/PIS036

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236921903

http://www.w3.org/2001/XMLSchema#string

P698

23687574

http://www.w3.org/2001/XMLSchema#string

P932

3656554

http://www.w3.org/2001/XMLSchema#string